Medivation is a bio-pharmaceutical company based in San Francisco, California. It focuses in producing drugs for the treatment of serious diseases. MDVN collaborates with Astellas for the development and marketing of its prostate cancer drug.
Columbus increased its shares in Medivation by 134% in the third quarter. The company now comprises 1.22% of the asset manager's total holdings. CCI initiated its position during the first quarter, and then drastically increased it by 259% in the second quarter.
Recent reports show that the sales of Medivation's prostate cancer drug Xtandi have just surpassed analysts' expectations. The company's marketer reported third quarter revenue of $14 million even when the drug hit the market only in the middle of September. Thus, the quarterly revenue growth (yoy) is 171.61%. The stocks year-to-date performance has improved by about 106%.